OSUCCC Administration, rated as "Outstanding to Excellent" in 1999 and "Outstanding" in 2004, is responsible for the accounting, finance, human resources, information systems, meeting planning, grants administration, document preparation, procurement, travel, marketing and facilities management required to support the operations of the OSUCCC. Since 2004, The OSUCCC Administration infrastructure has expanded from 30.6 FTEs to 59 FTEs in order to adequately support: 1) a 72% increase in NCI funding and a 35% increase in overall peer-reviewed, cancer-relevant grant funding;2) an increase in the number of shared resources, from 16 to 18 with 2 more in development;3) the recruitment of 159 new cancer faculty;4) increased inter- and intra-programmatic research activities including 41 funded and/or newly submitted POl, P50, U01, U10, SPORE and Tobacco Settlement grant applications;5) over a 274% increase in investigator-initiated clinical trial accrual;6) management of approximately 300,000 square feet of research and administration space and ongoing planning efforts for the construction of an additional 125,000 nsf of new research space by 2016;and, 7) expanded planning and evaluation activities. Overall, the responsibility of OSUCCC Administration continues to be to support and facilitate the conduct of leading-edge cancer research. The CCC administrative support offices were relocated in 2006 from space within the Martha Morehouse Medical Complex to the Ackerman facility located 0.3 miles from the OSUCCC research and medical facilities. The Ackerman facility provides 13,000 nsf (a 217% increase in space) of centralized and fully equipped office space to comfortably accommodate the large administrative team while also providing room for future growth. In addition to full tele- and videoconferencing capabilities, a continuous shuttle service provides convenient and efficient access for Administration to all OSUCCC members and staff. As detailed in the table at the end of this section, in year 1 of the 2010 CCSG renewal, we are requesting funding for 6.75 of the 59 FTEs comprising OSUCCC Administration. In dollars, the CCSG request would fund 14.8% of the total OSUCCC Administration costs with the remaining 85.2% being institutionally supported. Overall, in year 1, Administration represents 10.9% ofthe total CCSG budget request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601803
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$419,142
Indirect Cost
$144,295
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9
Eloy, Josimar O; Petrilli, Raquel; Topan, José Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82
Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86
Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9
Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94
Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527
DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198
Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct. Mol Endocrinol 30:783-95

Showing the most recent 10 out of 1929 publications